Haemonetics (HAE)
(Delayed Data from NYSE)
$73.24 USD
-1.34 (-1.80%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $73.20 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
HAE 73.24 -1.34(-1.80%)
Will HAE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HAE
After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)
HAE vs. BSX: Which Stock Is the Better Value Option?
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for Haemonetics (HAE) Stock Options
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
Other News for HAE
Haemonetics price target lowered by $9 at Citi, here's why
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Haemonetics Announces Full Market Release for VASCADE MVP? XL Vascular Closure System
Haemonetics announces full market release of Vascade MVP XL
Haemonetics Corporation: Strong Growth and Innovation Justify a Buy Rating